FERMENTA BIOTECH LIMITED — Board/Management Information 2021

Sep 3, 2021

==> picture [451 x 70] intentionally omitted <==

Ref: F.No.:49

September 3, 2021

Corporate Relations BSE Limited, Phiroze Jeejeebhoy Towers, Dalal Street, Fort, Mumbai – 400 001

Dear Sirs,

Sub.: Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (‘Listing Regulations’) Ref: Scrip Code: 506414

Pursuant to the provisions of Regulation 30 of Listing Regulations, we hereby inform that the members of the Company at the 69[th] Annual General Meeting held today (‘AGM’), have approved:

• (a) Appointment of Mr. Krishna Datla as a Whole-time Director of the Company, designated as Executive ViceChairman, for a period of 3 years w.e.f. May 9, 2021;

• (b) Appointment of Mr. Prashant Nagre, as a Director of the Company; and

• (c) Appointment of Mr. Prashant Nagre as Managing Director of the Company for a period of 3 years w.e.f. May 9, 2021.

Requisite details of directors in terms of SEBI Circular No. CIR/CFD/CMD/4/2015 dated September 9, 2015 and affirmation pursuant to BSE Circular LIST/COMP/14/2018-19 dated June 20, 2018 are provided in Annexure 1 in respect of Mr. Krishna Datla and Mr. Prashant Nagre.

The members also approved the appointment of Mr. Satish Varma (DIN – 00003255), who retired by rotation and, being eligible, offered himself for re-appointment;

Kindly take the above on your record. Thanking you, Yours faithfully,

For Fermenta Biotech Limited (Formerly known as DIL Limited)

Srikant Sharma Company Secretary & Vice President (Legal) Membership No. FCS3617

Encl: Annexure 1

==> picture [450 x 70] intentionally omitted <==

==> picture [451 x 70] intentionally omitted <==

			Annexure 1 Details of Directors	Annexure 1 Details of Directors
Sr.	Particulars	Mr. Krishna Datla		Mr. Prashant Nagre	Mr. Satish Varma
1	Reason for change viz. appointment, resignation, removal, death or otherwise	The Board of Directors at its meeting held on May 06, 2021, appointed Mr. Krishna Datla as a Whole-time Director of the Company, designated as the Executive Vice-Chairman, subject to members’ approval. The members at the AGM, approved the appointment of Mr. Krishna Datla as a Whole-time Director of the Company, designated as Executive Vice-Chairman, for a period of 3 years w.e.f. May 9, 2021.		The Board of Directors at its meeting held on May 06, 2021, appointed Mr. Prashant Nagre as an Additional Director of the Company. He is also appointed by the Board as the Managing Director of the Company, subject to members’ approval. The members at the AGM, approved the appointment of Mr. Prashant Nagre as Director of the Company, not liable to retire by rotation. The members also approved appointment of Mr. Prashant Nagre as Managing Director of the Company for a period of 3 years w.e.f. May9, 2021.	Re-appointment pursuant to retirement by rotation under Section 152 of the Companies Act, 2013
2	Date of appointment/cessation (as applicable) & term of appointment	Mr. Krishna Datla has been appointed a Whole-time Director of the Company, designated as the Executive Vice-Chairman, with effect from 9thMay, 2021, for a term of 3 (three) years.		Mr. Prashant Nagre has been appointed as - (a) Director w.e.f. 6thMay, 2021, not liable to retire by rotation; (b) Managing Director with effect from 9thMay 2021, for a term of 3 (three) years.	Re-appointed on September 3, 2021
3	Brief profile (in case of appointment)	Mr. Krishna Datla is a promoter and a Whole-time Director of the Company, designated as the Executive Vice-Chairman of the Company with effect from 9th May, 2021 to 8thMay, 2024. He has played a key role in the Company’s decision- making process and also oversees new businesses of the Company.		Mr. Prashant Nagre was elevated to the position of Managing Director with effect from 9thMay, 2021. Nearly three decades in the pharmaceuticals industry, he has in-depth experience across spheres encompassing the API business, production, Research and Development and regulatorycompliances.	Mr. Satish Varma has over 26 years of experience. He has an extensive and diverse operational, management and legal experience across the full scope of the FBL enterprise and was instrumental in the Solvay demerger in 2000 as well as the Crocin brand out-license in 1996, events that have shaped

==> picture [450 x 70] intentionally omitted <==

==> picture [451 x 70] intentionally omitted <==

		Credited with the integration of businesses across the various group companies, Mr. Krishna Datla has infused a strong sense of global vision thereby opening the opportunities across international markets. He has over 20 years of experience. Mr. Datla is a Commerce Graduate from Mumbai University.	He has led corporate strategy, business operations and demand- driven innovation for FBL’s three business verticals viz., Vitamin D and other APIs, Integrated Biotechnology and Environmental Solutions. He holds a master’s degree in management sciences, and also a Post Graduate Diploma in International Trade (IIFT, New Delhi), besides a Degree in Pharmacy.	the current strategic platform of the Company. Took direct operational responsibility of the Vitamin D3 business in 1998 and has led its growth.
4	Disclosure of relationships between directors (in case of appointment of a director).	He is relative of Ms. Anupama Datla Desai, Executive Director and Ms. Rajeshwari Datla, Non- Executive Director, as per Section 2(77) of the Companies Act, 2013	Nil	Nil
5	Affirmation pursuant to BSE Circular LIST/COMP/14/2018-19 dated June 20, 2018 that director debarred from holding the office of director	It is affirmed that Mr. Krishna Datla is not debarred from holding the office(s) of director by virtue of any SEBI order or any other such authority.	It is affirmed that Mr. Prashant Nagre is not debarred from holding the office(s) of director by virtue of any SEBI order or any other such authority.	It is affirmed that Mr. Satish Varma is not debarred from holding the office(s) of director by virtue of any SEBI order or any other such authority.

==> picture [450 x 70] intentionally omitted <==

---